Early is not always better. (00:21) Jason Moser and Mary Long discuss the semiconductor supply chain, ASML earnings, and what’s ailing the pharmacy industry. Then, (16:40) Motley Fool contributor Brian Orelli joins for a look at how the genetic testing company 23andme went from a $6 billion valuation to a penny stock in a mere three years … and where the company (and its data) might go from here. Vote for Motley Fool Money in the 2024 Signal Awards for Best Money and Finance podcast: https://vote.signalaward.com/PublicVoting#/2024/shows/general/money-finance Learn more about the Range Rover Sport at www.landroverusa.com Companies discussed: ASML, WBA, CVS, ME, GSK Host: Mary Long Guests: Jason Moser, Brian Orelli Producer: Ricky Mulvey Engineers: Tim Sparks, Rick Engdahl Learn more about your ad choices. Visit megaphone.fm/adchoices
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other episodes from Motley Fool Money
Transcribed and ready to explore now
Interview with MichaelAaron Flicker: Hacking the Human Mind
21 Dec 2025
Motley Fool Money
How to Review and Rebalance Your Portfolio
20 Dec 2025
Motley Fool Money
Hidden Gem Stocks We Love at the End of the Year
18 Dec 2025
Motley Fool Money
Don’t Call It a Comeback
10 Dec 2025
Motley Fool Money
$70 billion and Chill
09 Dec 2025
Motley Fool Money
Profitability Predictions and Paramount Punches Back
08 Dec 2025
Motley Fool Money